Journal of Pharmacovigilance

Department of Medicine, Monmouth Medical Center, New Jersey, USA

Publications

• Case Report   
  Acute Hepatic Failure with Hyperbilirubinemia in a Cirrhotic Patient Receiving Glecaprevir and Pibrentasvir (Mavyret^®) For Hepatitis C Infection
  Author(s): Germin Fahim*, Farah Heis, Mohamad Hamad, Dana Ahmad, Hardik Fichadiya and Ahmad Al-Alwan
  
  The Hepatitis C Virus (HCV) causes both acute and chronic hepatitis C infection, requiring treatment with Direct Acting Antiviral (DAA) therapy for 8-24 weeks. Glecaprevir/pibrentasvir (Mavyret®) is a fixed-dose combination of an NS3/4A protease inhibitor and NS5A inhibitor, respectively, targeted to decrease replication of the Hepatitis C Virus (HCV). Since its initial approval in 2017, it has gained indications to include management of pan-genotypic HCV with or without compensated cirrhosis in treatment-naïve or treatment-experienced individuals from children 3 years of age and older. The most common reported adverse effects are headache and fatigue; however, the FDA recently published a warning about rare occurrence of serious liver injury with the use of glecaprevir/pibrentasvir in some patients with advanced liver disease. We disc.. View more»
  

  DOI: 10.35248/2329-6887.22.10.399

  Abstract HTML PDF